``Marion Laboratories (MKC, NYSE, 46, 12-month range 22 1/2-50) will outperform every drug stock by 2 1/2 times, according to Richard Stover of Smith Barney,`` notes Portfolio Letter from New York. ``Marion's drug, Cardizem, is currently marketed for the treatment of angina. However, a recent report, which appeared in the New England Journal of Medicine, has shown that Cardizem also has a broad use in lowering high blood pressure and reducing the risk of a second heart attack in certain patients. Therefore, the customer base for the drug could increase dramatically from the current 4-5-million to as many as 60-million. Stover expects the drug company to post a 40 percent growth rate through 1990. He rates the issue a `strong buy.``'